沙库巴曲缬沙坦在心律失常治疗中的研究进展  

Advances in the treatment of arrhythmias with sacubitril/valsartan

作　　者：曹馨瑞 严思敏 姚惠敏 葛卫红[2] CAO Xin-rui;YAN Si-min;YAO Hui-min;GE Wei-hong(Nanjing Drum Tower Hospital Clinical College,Nanjing University of Chinese Medicine,Nanjing 210029;Department of Pharmacy,Affiliated Drum Tower Hospital of Nanjing University,Nanjing 210008)

机构地区：[1]南京中医药大学鼓楼临床医学院,南京210029 [2]南京大学医学院附属鼓楼医院药学部,南京210008

出　　处：《中南药学》2023年第3期726-730,共5页Central South Pharmacy

基　　金：江苏省药学会恒瑞医院药学基金(No.H202020)。

摘　　要：沙库巴曲缬沙坦是一种脑啡肽-血管紧张素受体拮抗剂(ARNI)。ARNI在肾素-血管紧张素-醛固酮系统(RAAs)和利钠肽系统(NPs)中的协同作用,让它在心力衰竭、高血压等临床试验中疗效显著,从而在心血管领域获得非常高的地位。近年来的研究表明,沙库巴曲缬沙坦对房性和室性心律失常患病率的影响结论不一,对于沙库巴曲缬沙坦治疗心律失常的作用也缺乏整体认识。本文对沙库巴曲缬沙坦在心律失常中的有效性和安全性进行综述和评价,并阐释沙库巴曲缬沙坦与心律失常之间可能的联系。Sacubitril/valsartan,an angiotensin receptor neprilysin inhibitor(ARNI),plays a synergistic role in the renin-angiotensin-aldosterone system(RAAs)and natriuretic peptides(NPs).Owing to its significant efficacy in clinical trials for heart failure and hypertension,ARNI gains a very high status in the treatment of cardiovascular diseases.Experiments in recent years have shown that the effect of sacubitril/valsartan on the morbidity of atrial and ventricular arrhythmias is inconsistent,and an overall understanding of its effect on arrhythmias is lacking.This review evaluated the efficacy and safety of sacubitril/valsartan in arrhythmias and explained the possible link between sacubitril/valsartan and arrhythmias.

关 键 词：沙库巴曲缬沙坦 心律失常 脑啡肽-血管紧张素受体拮抗剂 

分 类 号：R972[医药卫生—药品]